Drug firm Lupin Tuesday said it has launched generic Silodosin capsules, used for treatment of signs and symptoms of benign enlargement of the prostate gland, in the US market.
The company has launched its Silodosin capsules in the strengths of 4 mg and 8 mg after receiving an approval from the United States Food and Drug Administration (USFDA) earlier, the company said in a statement.
The company's product is generic equivalent of Allergan's Rapaflo capsules, it added.
As per IQVIA MAT September 2018 data, Rapaflo had annual sales of USD 198.5 million in the US, Lupin said.
The capsules are indicated for the treatment of the signs and symptoms of prostatic hyperplasia (BPH), it added.
Shares of Lupin today closed at Rs 888.05 per scrip on BSE, down 1.14 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app